Noxopharm (ASX:NOX) share price edges lower after clinical trial update

The clinical-stage drug development company's shares have taken a tumble today

| More on:
Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Noxopharm Ltd (ASX: NOX) share price is falling this afternoon. This comes after the company released an update about its DARRT-2 clinical trial.

At the time of writing, Noxopharm shares are swapping hands for 69 cents apiece, down 1.43%

What did Noxopharm announce?

Investors are selling Noxopharm shares after digesting the clinical-stage drug development company's latest release.

According to Noxopharm, it is on track to undertake a multi-national study for its flagship cancer-fighting drug, Veyonda. The drug is used in conjunction with radiotherapy.

Titled DARRT-2 (Direct and Abscopal Response to RadioTherapy), the phase 2 trial aims to treat late-stage prostate, breast and lung cancer patients for whom traditional treatment options such as chemotherapy and radiotherapy have failed.

The trial seeks to generate the phenomenon of the abscopal response in cancer patients. This is when a low dose of radiation not only shrinks a targeted tumour, but triggers an immune response that results in other tumours melting away. Noxopharm hopes the cancer cells could be eradicated within a matter of weeks.

The phase 2 trial is seeking to recruit 100 participants across 15 sites in Australia, the United States, France, and Hungary. International contract research organisation Parexel has been appointed to oversee the study.

Management commentary

Noxopharm CEO and managing director Dr Graham Kelly said:

The abscopal response is a highly attractive cancer treatment goal because it provides the opportunity for a major anti-cancer outcome from a generally safe and minimally invasive treatment. The challenge is that it is a very rare phenomenon that to date has proven difficult to reproduce on a consistent basis.

Recent research has pointed to a reason for this being the need to block a certain type of repair process called autophagy of mitochondrial DNA damaged by the radiation. Other research points to idronoxil, the active ingredient in Veyonda, blocking autophagy. It is the combination of that effect and the drug's known immuno-stimulatory effects, together with the earlier DARRT-1 trial data, that provides the confidence that we might have the ability to achieve consistently higher response rates to make DARRT a practical treatment option.

Noxopharm share price summary

Despite today's dip, Noxopharm shares have surged by more than 250% over the past 12 months. The company's share price reached a 52-week high of 99 cents in February, before treading lower from profit taking.

On valuation grounds, Noxopharm has a market capitalisation of roughly $201 million, with approximately 288 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »